S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results

Nevro (NVRO) Stock Price, News & Analysis

$15.11
-0.53 (-3.39%)
(As of 02/27/2024 ET)
Today's Range
$15.00
$15.90
50-Day Range
$15.11
$22.31
52-Week Range
$13.98
$39.67
Volume
526,808 shs
Average Volume
466,024 shs
Market Capitalization
$550.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.23

Nevro MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
53.7% Upside
$23.23 Price Target
Short Interest
Bearish
12.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of Nevro in the last 14 days
Based on 39 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.53) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.61 out of 5 stars

Medical Sector

455th out of 944 stocks

Surgical & Medical Instruments Industry

53rd out of 92 stocks


NVRO stock logo

About Nevro Stock (NYSE:NVRO)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

NVRO Stock Price History

NVRO Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Nevro (NYSE:NVRO) Stock Price Down 7% on Analyst Downgrade
Nevro (NYSE:NVRO) Downgraded to Market Perform at Oppenheimer
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
StockNews.com Lowers Nevro (NYSE:NVRO) to Sell
Nevro just downgraded at Oppenheimer, here's why
Nevro (NYSE:NVRO) Shares Gap Down on Analyst Downgrade
Why Nevro Stock Lagged the Market on Thursday
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
Analyst Scoreboard: 4 Ratings For Nevro
Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript
Nevro: Q4 Earnings Snapshot
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
NVRO Mar 2024 22.500 call
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
2/28/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Fax
N/A
Employees
1,087
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.23
High Stock Price Target
$40.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+53.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

Net Income
$-92,210,000.00
Pretax Margin
-23.02%

Debt

Sales & Book Value

Annual Sales
$425.17 million
Book Value
$8.05 per share

Miscellaneous

Free Float
35,119,000
Market Cap
$550.00 million
Optionable
Optionable
Beta
0.94
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Roderick H. MacLeod (Age 57)
    Senior VP & CFO
    Comp: $729.61k
  • Mr. Kashif RashidMr. Kashif Rashid (Age 50)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $703.35k
  • Mr. Kevin R. Thornal (Age 50)
    President, CEO & Director
  • Mr. Richard B. Carter (Age 53)
    Chief Accounting Officer
  • Mr. Christofer Christoforou (Age 54)
    Senior Vice President of Technical Operations
    Comp: $367.4k
  • Geeta Kaveti
    VP and Chief Compliance & Privacy Officer
  • Mr. Jon R. Shear
    Senior Vice President of Corporate Development
  • Meredith Vornholt
    Vice President of Global Marketing
  • Ms. Shana D. Ross M.B.A.
    Senior VP & Chief of Human Resources Officer
  • Dr. David Caraway M.D. (Age 67)
    Ph.D., Senior VP & Chief Medical Officer














NVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price target for 2024?

13 brokers have issued twelve-month target prices for Nevro's stock. Their NVRO share price targets range from $15.00 to $40.00. On average, they predict the company's stock price to reach $23.23 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2024?

Nevro's stock was trading at $21.52 at the start of the year. Since then, NVRO shares have decreased by 29.8% and is now trading at $15.11.
View the best growth stocks for 2024 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) posted its quarterly earnings data on Wednesday, November, 1st. The medical equipment provider reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.77) by $0.12. The medical equipment provider had revenue of $103.86 million for the quarter, compared to analyst estimates of $95.87 million. Nevro had a negative trailing twelve-month return on equity of 30.22% and a negative net margin of 21.69%. The company's revenue was up 3.4% on a year-over-year basis. During the same period last year, the company earned ($0.62) earnings per share.

What ETFs hold Nevro's stock?
What guidance has Nevro issued on next quarter's earnings?

Nevro updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.0 million-$99.0 million, compared to the consensus revenue estimate of $98.7 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.23%), Armistice Capital LLC (8.77%), Braidwell LP (4.91%), Goldman Sachs Group Inc. (2.89%), Palo Alto Investors LP (2.07%) and Principal Financial Group Inc. (1.99%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVRO) was last updated on 2/28/2024 by MarketBeat.com Staff